Vertex Pharmaceuticals VRTX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's free cash flow?
- Vertex Pharmaceuticals (VRTX) reported free cash flow of $1.29B in Q1 2026.
- How has Vertex Pharmaceuticals's free cash flow changed year-over-year?
- Vertex Pharmaceuticals's free cash flow increased by 66.4% year-over-year, from $778.2M to $1.29B.
- What is the long-term trend for Vertex Pharmaceuticals's free cash flow?
- Over 3 years (2022 to 2025), Vertex Pharmaceuticals's free cash flow has grown at a -6.6% compound annual growth rate (CAGR), from $3.93B to $3.19B.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.